The Fool was on top of things this week, from the marquee issues of the day to the smaller corners of the market. We've even thrown in a list of must-have stocks.
Dear SEC, Welcome Back
Fool analyst Nick Kapur pulled the SEC aside for a little chat, reproaching, encouraging, and advising the watchdog as it takes on Goldman Sachs
"Now, I know you're excited to be back, and trust us, we're happy to see you," Nick wrote. "But we do have one word of advice before you put those gloves back on. You can't just go right out and expect to be No. 1 again. It takes hard work to be the fearsome fighter you once were."
And while the SEC's choice of Goldman as supreme foe was inspiring, Nick had concerns. "Whatever happened to scheduling a few tune-up fights before the title fight, you know? Put a few easy companies on the mat, a few execs in the can, get your wind back," he said.
Click to the story for Nick's advice on what the SEC must do to reclaim respect.
LogMeIn and Fill 'Er Up
You never know when you might stumble across a good investment. Fool contributor Rich Smith found LogMeIn
"An investor by nature, this piqued my curiosity, and I picked up a few shares to keep my interest alive," Rich related. He's been rewarded with double-digit gains. "For the time being, it's a fun ride," Rich said.
Investing can be fun, but take a lesson from Rich, and don't get caught up in what might be just a crush on a company. Click to the article to see Rich's review of LogMeIn's free cash flow, and his realistic take on the company's future.
Must-Have Stocks for the Next Correction
No rest for the wicked, or for stock pickers. With another correction on its way, investors might want to protect their portfolios using short-selling or the delightfully named "strangles." Or how about something simpler?
"Technically, it's playing defense more than it is hedging, but the results are nonetheless impressive," wrote Fool contributor Mike Pienciak. "It's called -- are you ready? -- stock picking."
Mike put forward seven stocks that significantly outperformed the market during the two worst periods of the 2008-09 financial crisis. He then took readers through a rundown of prospects at Teva Pharmaceutical
Click to the story to see Mike's full list of stocks.
Fool online editor Kris Eddy owns no shares of any stocks mentioned in this article. Try any of our investing newsletters free for 30 days. The Fool's disclosure policy tries to go placidly amid the noise and haste.